BARNETT INTERNATIONAL OFFERS DRUG DEVELOPMENT CONFERENCES IN EUROPE
BOSTON, MA, March 10, 2004 — Barnett International, a division of PAREXEL International Corporation (Nasdaq: PRXL), announces the expansion of its drug development educational conference offerings in Europe. Barnett will provide its broad array of in-depth, unbiased conferences in Europe to professionals in the pharmaceutical, biotechnology and medical device industries. These educational offerings cover a multitude of topics in the field of clinical research and development. Barnett educational conferences are designed to address the latest issues affecting the drug development process and increase the knowledge base of each attendee.
"The goal of our educational conferences is to provide attendees with the opportunity to learn from highly regarded industry experts, network with peers and gain in-depth, hands-on knowledge that can be put to use immediately," said Ann Carraher, Vice President, Educational Services, Barnett International. "Our expansion provides European professionals with closer proximity to our broad range of clinical research and development educational conferences."
About the Conferences
Phase IV Clinical Research Programs
Strategies for Maximizing the Scientific and Commercial Benefit of Peri and Post Approval Studies
June 28-29, 2004, Brussels, Belgium
Strategies for Successful Patient Recruitment
Identifying Patient Recruitment and Enrollment challenges in EU and
Examining Best Practices for Success
June 28-29, 2004, Brussels, Belgium
Meeting Global Safety and Risk Management Regulatory Guidelines for the
Detection, Evaluation, and Reporting of Adverse Events
June 30-July1, 2004, Brussels, Belgium
Pediatric Clinical Trials
Current Regulations and Strategies for Operating Successful Pediatric Trials
in the Pharmaceutical Industry
June 30-July 1, 2004, Brussels, Belgium
For further information, contact us at 800 856-2556 x2200 or firstname.lastname@example.org. To register online, please visit, www.barnettinternational.com/edu-about.jsp.
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 37 countries around the world, and has 5,050 employees.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. PAREXEL's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to win new business, manage growth, and attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2003 as filed with the SEC on February 10, 2004, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent PAREXEL’s estimates as of the date of this release. PAREXEL specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing PAREXEL’s estimates or views as of any date subsequent to the date of this press release.